These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31119047)

  • 21. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Krukovine Suppresses KRAS-Mutated Lung Cancer Cell Growth and Proliferation by Inhibiting the RAF-ERK Pathway and Inactivating AKT Pathway.
    Lai H; Wang Y; Duan F; Li Y; Jiang Z; Luo L; Liu L; Leung ELH; Yao X
    Front Pharmacol; 2018; 9():958. PubMed ID: 30186180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
    Yoon YK; Kim HP; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
    Mol Carcinog; 2010 Apr; 49(4):353-62. PubMed ID: 20358631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirtuin 7 promotes non‑small cell lung cancer progression by facilitating G1/S phase and epithelial‑mesenchymal transition and activating AKT and ERK1/2 signaling.
    Zhao Y; Ye X; Chen R; Gao Q; Zhao D; Ling C; Qian Y; Xu C; Tao M; Xie Y
    Oncol Rep; 2020 Sep; 44(3):959-972. PubMed ID: 32705247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 27. A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.
    Zou ZQ; Zhang XH; Wang F; Shen QJ; Xu J; Zhang LN; Xing WH; Zhuo RJ; Li D
    Int J Mol Med; 2009 Jul; 24(1):97-101. PubMed ID: 19513541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
    Huang RS; Zheng YL; Zhao J; Chun X
    Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].
    Li ZW; Yang ZL; Feng HL; Bian XC; Liu YY; Liu YQ
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):330-5. PubMed ID: 24004591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors.
    Wei XL; Liu FR; Liu JH; Zhao HY; Zhang Y; Wang ZQ; Qiu MZ; Xu F; Yu QQ; Du YW; Shi YX; Wang DS; Wang FH; Xu RH
    Nat Commun; 2022 Nov; 13(1):7012. PubMed ID: 36385120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.
    Chiron D; Martin P; Di Liberto M; Huang X; Ely S; Lannutti BJ; Leonard JP; Mason CE; Chen-Kiang S
    Cell Cycle; 2013 Jun; 12(12):1892-900. PubMed ID: 23676220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
    Jansen VM; Bhola NE; Bauer JA; Formisano L; Lee KM; Hutchinson KE; Witkiewicz AK; Moore PD; Estrada MV; Sánchez V; Ericsson PG; Sanders ME; Pohlmann PR; Pishvaian MJ; Riddle DA; Dugger TC; Wei W; Knudsen ES; Arteaga CL
    Cancer Res; 2017 May; 77(9):2488-2499. PubMed ID: 28249908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nootkatone, an AMPK activator derived from grapefruit, inhibits KRAS downstream pathway and sensitizes non-small-cell lung cancer A549 cells to adriamycin.
    Hung LVM; Moon JY; Ryu JY; Cho SK
    Phytomedicine; 2019 Oct; 63():153000. PubMed ID: 31280139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erratum to Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer.
    Wang Y; Li X; Liu X; Chen Y; Yang C; Tan C; Wang B; Sun Y; Zhang X; Gao Y; Ding J; Meng L
    Cancer Biol Med; 2019 Nov; 16(4):836. PubMed ID: 31908900
    [No Abstract]   [Full Text] [Related]  

  • 35. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines.
    Ling YH; Li T; Yuan Z; Haigentz M; Weber TK; Perez-Soler R
    Mol Pharmacol; 2007 Aug; 72(2):248-58. PubMed ID: 17456787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual inhibition of MEK and p38 impairs tumor growth in
    Sunaga N; Miura Y; Tsukagoshi Y; Kasahara N; Masuda T; Sakurai R; Kaira K; Hisada T
    Oncol Lett; 2019 Mar; 17(3):3569-3575. PubMed ID: 30867799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.
    Tsai AC; Pai HC; Wang CY; Liou JP; Teng CM; Wang JC; Pan SL
    Br J Pharmacol; 2014 Jan; 171(1):122-33. PubMed ID: 24116948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-34b-3p represses cell proliferation, cell cycle progression and cell apoptosis in non-small-cell lung cancer (NSCLC) by targeting CDK4.
    Feng H; Ge F; Du L; Zhang Z; Liu D
    J Cell Mol Med; 2019 Aug; 23(8):5282-5291. PubMed ID: 31199581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-30a suppresses non-small cell lung cancer progression through AKT signaling pathway by targeting IGF1R.
    Wen XP; Ma HL; Zhao LY; Zhang W; Dang CX
    Cell Mol Biol (Noisy-le-grand); 2015 May; 61(2):78-85. PubMed ID: 26025408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
    Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
    J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.